Teva Pharmaceutical Industries (NYSE: TEVA) today announced the release of limited doses of the FDA-approved generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the US. Teva’s generic version of the EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen® (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019. The publically-available Wholesale Acquisition Cost (WAC)2 for the product is $300.
Brendan O’Grady, EVP and Head of North America Commercial at Teva said, “We’re pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience life-threatening allergic emergencies and we’re fully dedicated toward ensuring additional supply in 2019.”
With over 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in seven generic prescriptions dispensed in the US is filled with a Teva generic product.
https://www.streetinsider.com/Corporate+News/Teva+Pharma+%28TEVA%29+Says+Generic+Version+of+EpiPen+Auto-Injector+0.3+mg+Now+Available+in+Limited+Quantity+in+U.S./14864936.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.